Previous close | 69.30 |
Open | 69.27 |
Bid | 61.50 |
Ask | 62.35 |
Strike | 85.00 |
Expiry date | 2024-01-19 |
Day's range | 69.27 - 69.40 |
Contract range | N/A |
Volume | |
Open interest | 6 |
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
In either case, it's a good idea to add some dividend stocks to your portfolio. If you want to benefit from passive income and potential growth, I've got two stocks in mind. The stocks I'm talking about also have reached a turning point that could lead to earnings growth down the road.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports continued innovation and provides cutting-edge products and technologies to help practitioners and patients' aesthetics needs today and for the future.